Emerging small molecule antivirals may fit neatly into COVID-19 treatment

Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although most are not well established; among these are several small molecule antiviral agents. Intravenous remdesivir is an established treatment worldwide for inpatients and in some countries is also available for use in non-hospitalised high risk patients to prevent progression to severe disease and hospitalization. Oral molnupiravir and oral nirmatrelvir-ritonavir are also available in several countries to prevent progression to severe disease and hospitalization for high-risk outpatients. Many other antiviral small molecules that may have therapeutic potential are under investigation in clinical trials. This article provides a summary of key molecular targets, pharmacology and preliminary data on the efficacy and safety of small molecule antiviral agents being investigated for the treatment of COVID-19.

Automated summary

There are numerous treatments available for COVID-19, including small molecule antiviral agents such as remdesivir, molnupiravir, and nirmatrelvir-ritonavir. Many other small molecule antiviral agents are also being studied in clinical trials for their therapeutic potential.